BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
NCT00017056 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-06-18
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent metastatic stomach cancer that has been previously treated with chemotherapy.
Conditions
- Esophageal Cancer
- Gastric Cancer
Interventions
- DRUG
-
ixabepilone
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Manish A. Shah, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-02-28
- Primary Completion
- 2002-01-31
- Completion
- 2002-01-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
NCT00006081 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
NCT04021108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
NCT00003192 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer
NCT00611507 ·Status: COMPLETED ·Phase: PHASE2
-
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
NCT03469557 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
NCT02016534 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
NCT00084617 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
NCT00003172 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT00074009 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT02872116 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
NCT02202759 ·Status: TERMINATED ·Phase: PHASE2
-
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
NCT00447330 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00080002 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
NCT00075465 ·Status: UNKNOWN ·Phase: PHASE2
-
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
NCT00397904 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
NCT00020761 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
NCT00087503 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
NCT06846346 ·Status: RECRUITING ·Phase: PHASE2
-
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
NCT06361576 ·Status: COMPLETED
-
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
NCT01590719 ·Status: COMPLETED ·Phase: PHASE2
-
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
NCT04345770 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
NCT01630083 ·Status: COMPLETED ·Phase: PHASE2